Erin Schenk MD, PhD
Assistant Professor of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Denver, Colorado
Dr. Erin Schenk is an Assistant Professor of Medicine in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus. She specializes in thoracic oncology.
Dr. Schenk received her MD and PhD from the Mayo Clinic Medical Scientist Training Program in Rochester, Minnesota. Her thesis work focused on the adaptive immune response to cancer antigens. She completed her internal medicine residency and fellowship at Mayo Clinic with a continued focus in tumor immunology through the Clinician-Investigator Training Program. The Schenk Lab is part of the Thoracic Oncology Research Initiative at the University of Colorado and investigates the lung cancer tumor microenvironment as a contributor to lung cancer progression and treatment resistance.
Dr. Schenk received her MD and PhD from the Mayo Clinic Medical Scientist Training Program in Rochester, Minnesota. Her thesis work focused on the adaptive immune response to cancer antigens. She completed her internal medicine residency and fellowship at Mayo Clinic with a continued focus in tumor immunology through the Clinician-Investigator Training Program. The Schenk Lab is part of the Thoracic Oncology Research Initiative at the University of Colorado and investigates the lung cancer tumor microenvironment as a contributor to lung cancer progression and treatment resistance.
Recent Contributions to PracticeUpdate:
- Alectinib: A Step Forward in the Second-Line Treatment of ALK+ NSCLC
- No Survival Benefit From Bevacizumab in Elderly GBM Patients
- An Overview of CDK 4/6 Inhibitors for First Line ER+ Advanced Breast Cancer
- Rationale and Use of New Drugs for Opioid-Induced Constipation in Patients With Cancer
- PARP Inhibitors and Carboplatin for Neoadjuvant Triple Negative Breast Cancer Treatment—A West Cancer Center Perspective
- Unmet Needs for CINV in Highly Emetogenic Chemotherapy: The Role of NEPA
- Adjuvant Chemotherapy or Adjuvant Chemoradiotherapy for Gastric Cancer?—A West Cancer Center Perspective
- New Phase 3 Data on Targeting c-MET in Advanced Hepatocellular Carcinoma—A West Cancer Center Perspective
- Implications of New Nivolumab and Ipililumab Combination Data in Melanoma Brain Metastases—A West Cancer Center Perspective
- Perspectives on BRAF and MEK Inhibitor Combinations in BRAF-Mutant Melanoma—A West Cancer Center Perspective